Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 84, Issue 9, Pages 1989-1999Publisher
WILEY
DOI: 10.1111/bcp.13628
Keywords
Candida spp; fluconazole; micafungin; neonate; pharmacokinetics; safety
Categories
Funding
- European Commission [223 614]
- GlaxoSmithKline
Ask authors/readers for more resources
AIMS The pharmacokinetics (PK) of fluconazole and micafungin differ in neonates compared with children and adults. Dosing instructions in product labels appear to be inconsistent with the emerging scientific evidence. Limited information is available on the safety profile of these agents in neonates. Our objective was to study the population PK and safety of both drugs, randomly administered in neonates with suspected or confirmed systemic candidiasis. METHODS Neonates were randomized 1: 1 to fluconazole (loading dose 25mg kg(-1); maintenance dose 12mgkg(-1) day(-1) or 20mgkg(-1) day-1, respectively, for infants < 30 weeks or >= 30 weeks' corrected gestational age) or micafungin (loading dose 15 mg kg(-1) day(-1); maintenance dose 10mg kg(-1) day(-1)). PK samples were taken on treatment days 1 and 5. Population parameters were determined using NONMEM and Monte Carlo simulations performed to reach predefined targets. Clinical and laboratory data, and adverse events were collected up to 36 weeks' corrected gestational age or hospital discharge. RESULTS Thirty-six neonates were enrolled. The median (range) gestational age was 28.2 (24.1-40.1) and 26.8 (23.5-40.0) weeks for fluconazole and micafungin, respectively. Based on 163 PK samples, the median population clearance (l h(-1) kg(-1)) and volume of distribution (l kg(-1)) for fluconazole were: 0.015 [95% confidence interval (CI) 0.008, 0.039] and 0.913, and for micafungin were: 0.020 (95% CI 0.010, 0.023) and 0.354 (95% CI 0.225, 0.482), respectively. The loading dose was well tolerated. No adverse events associated with micafungin or fluconazole were reported. CONCLUSION Based on Monte Carlo simulations, a loading dose for fluconazole and dosing higher than recommended for both drugs are required to increase the area under the plasma drug concentration-time curve target attainment rate in neonates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available